CASE REPORT Open Access

Primary hyperparathyroidism presenting as a brown tumor in the mandible: a case report



Bojin Xu^{1,2}, Jie Yu¹, Yingli Lu^{1*} and Bing Han^{1*}

Abstract

Background: Primary hyperparathyroidism is characterized by hypercalcemia and elevated or inappropriately normal serum levels of parathyroid hormone. Brown tumor of bone is a rare non-neoplastic lesion resulted from abnormal bone metabolism in hyperparathyroidism. However, nowadays, skeletal disease caused by primary hyperparathyroidism is uncommon. We report a case of brown tumor in the mandible as the initial exhibition of primary hyperparathyroidism associated with an atypical parathyroid adenoma.

Case presentation: The patient was a 49-year-old female, she had a pain mass on the right mandible a year ago and was treated with root canal therapy and marginal resection. After seven months, the mass recurred and enlarged. Enhanced CT scan, laboratory examination, Ultrasonography, ^{99m}Tc-MIBI SPECT-CT scintiscan and pathological examination were used to confirm the diagnosis of brown tumor. The patient's symptom improved after parathyroidectomy.

Conclusions: ^{99m}Tc-MIBI SPECT/CT scintigraphy is a highly sensitive examination of the localization diagnosis of hyperparathyroidism. Brown tumors should be considered in the differential diagnosis of osteolytic lesions to avoid unnecessary and harmful interventions.

Keywords: Brown tumor, Primary hyperparathyroidism, Mandible, Osteolytic lesions, Case report

Background

Primary hyperparathyroidism (PHPT) is a common endocrine disorder that is characterized by hypercalcemia and elevated or inappropriately normal serum levels of parathyroid hormone [1]. Single benign parathyroid adenoma is the most common cause of this disease (about 80% of the patients), whereas four gland parathyroid hyperplasia accounts for approximately 15–20% [2], multiple parathyroid adenomas for 5% and parathyroid cancer for < 1% of cases [1]. Brown tumor of bone, a rare non-neoplastic lesion resulted from abnormal bone metabolism in hyperparathyroidism, mostly affects facial bones, clavicle, ribs, pelvis, and femur [3]. When brown tumors associate with PHPT, they are most frequently

We report a case of brown tumor in the mandible as the initial exhibition of PHPT associated with an atypical parathyroid adenoma.

Case presentation

A 49-year-old female was referred to our hospital for a recurrent right mandible mass one year after primary excision. One year ago, she had a painful mass on the right mandible, which was first treated with root canal therapy and then by marginal resection of the right mandible at another medical institution. The postoperative pathology suggested giant cell granuloma. Seven months after surgery, the mass recurred and gradually enlarged.

On admission, an enhanced CT scan of the patient revealed a 3.6*2.1 cm lesion on the right mandible (Fig. 1a, b). A review of her previous pathological section revealed that the right mandible was rich in osteoclast-like polykaryotic giant cells. Based on this observation, the

Full list of author information is available at the end of the article



caused by adenomas [4]. However, skeletal disease secondary to PHPT is rare nowadays [5].

^{*} Correspondence: luyingli2008@126.com; hanbing1423@163.com

¹Institute and Department of Endocrinology and Metabolism, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

Xu et al. BMC Endocrine Disorders (2020) 20:6 Page 2 of 3




Fig. 1 (**a-b**) Enhanced computer tomography scan of the brown tumor in the mandible (yellow arrows). (**a**) Coronal CT and (**b**) axial CT. (**c-d**) ^{99m}Tc-MIBI of the parathyroid adenoma (red arrows): the early imaging (**c**) shows the radioactive concentration at the site of the left parathyroid, and the delayed imaging (**d**) shows that it did not degrade. (**e-h**) SPECT/CT scintigraphy revealed the low-density lesion with high radioactive uptake at the site of the left parathyroid (red arrows): (e-f) Axial, (**g**) sagittal, and (**h**) coronal images of the parathyroid adenoma

patient was further evaluated. Laboratory examination showed hypercalcemia: 2.81 mmol/l (normal range: $2.08-2.71 \, \text{mmol/l}$ hypophosphatemia: 0.66 mmol/l (normal range: 0.81-1.45 mmol/l), and a high PTH level: 916.0 pg/ml (normal range: 11.0-67.0 pg/ml). Ultrasonography revealed a hypoechoic mass on the left inferior thyroid lobe. 99mTc-MIBI SPECT-CT scintiscan demonstrated increased radiotracer uptake at the site of the left parathyroid, which was suggestive of parathyroid adenoma (Fig. 1c-h). Then, the patient underwent left parathyroidectomy surgery, and the pathological findings confirmed the diagnosis of parathyroid adenoma. Postoperative follow-up showed normal serum calcium and PTH levels, and the mandible mass decreased gradually.

Discussion and conclusions

In this case, the combination of hyperparathyroidism and the existence of giant cells in the mandibular pathology as well as gradual degradation of the tumor after operation supported the diagnosis of brown tumor.

Hyperparathyroidism may be primary, secondary and tertiary. Primary hyperparathyroidism is characterized by excessive PTH production and hypercalcemia, most frequently due to parathyroid adenoma. Secondary hyperparathyroidism is usually caused by vitamin D deficiency, malabsorption, or hypercalciuria. Low serum calcium levels resulted from primary diseases brings about redundant secretion of PTH. Tertiary

hyperparathyroidism, in most cases, developed from secondary hyperparathyroidism and evolves into a more severe circumstance with autonomous PTH secretion [1]. As in our case, laboratory findings showed hypercalcemia, hypophosphatemia and a high PTH level, which were consistent with PHPT.

Nowadays, with the increasingly available measurement of biochemical examination, the detection rate of hyperparathyroidism has been increased and PHPT has evolved into a typically asymptomatic disease, especially in developed countries where serum calcium levels are routinely measured [1, 2, 6]. A more extensive serum calcium screening in the general population may help to identify and treat the patients at an early stage.

Brown tumors are giant cell lesions caused by abnormal bone metabolism in hyperparathyroidism. Increased circulating PTH aggravates osteoclastic bone absorption, then leads to diffuse osteopenia, fractures or multiple circumscribed lytic lesions [7, 8]. There is dark, reddishbrown coloration induced by prominent intralesional hemorrhage and hemosiderin deposition, thus gives the lesion its name [9]. These bone-resorbing lesions can occur in any part in the bone, but they are rarely the initial signs of hyperparathyroidism [10]. They are believed to be gradually dissolved after surgical resection of the parathyroid gland [11].

The most prominent aspect of this case was the discovery of a brown tumor in the mandible, which was the

Xu et al. BMC Endocrine Disorders (2020) 20:6 Page 3 of 3

initial exhibition of an atypical parathyroid adenoma. However, the confirmed diagnosis was made after the surgery in the pathological findings, how to obtain certain diagnosis before the parathyroidectomy surgery remains to be explored. ^{99m}Tc-MIBI SPECT/CT scintigraphy is a highly sensitive examination of the localization diagnosis of hyperparathyroidism [12]. We suggest that clinicians bear in mind that brown tumors should be considered in the differential diagnosis of osteolytic lesions to avoid unnecessary and harmful interventions.

Abbreviations

^{99m}Tc-MIBI: ^{99m}Tc-sestamibi; CT: computed tomography; PHPT: Primary hyperparathyroidism; PTH: parathyroid hormone; SPECT: Single-Photon Emission Computed Tomography

Acknowledgements

Not applicable.

Authors' contributions

BX and BH participated in the diagnosis and treatment of the patient, provided follow-up, acquired clinical data, drafted and reviewed the manuscript. BH and JY conducted investigations, reviewed literature, and assisted in polishing the manuscript for final publication. YL played a role in guidance of the diagnosis and treatment of the patient, and contributed to give advice on the revision of the manuscript. All of the authors read and approved the final manuscript.

Funding

The study was supported by National Natural Science Foundation of China (Grant No.:81670717) in the collection of data and in writing the manuscript.

Availability of data and materials

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Institute and Department of Endocrinology and Metabolism, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. ²Department of Endocrinology, Shanghai Tongren Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Received: 12 October 2019 Accepted: 20 December 2019

References

- Walker MD, Silverberg SJ. Primary hyperparathyroidism. Nat Rev Endocrinol. 2018;14:115–25.
- Bilezikian JP, Bandeira L, Khan A, Cusano NE. Hyperparathyroidism. Lancet. 2018;391:168–78.
- 3. Agnihotri M, Kothari K, Naik L. Brown tumor of hyperparathyroidism. Diagn Cytopathol. 2017:45:43–4.
- Suarez-Cunqueiro MM, Schoen R, Kersten A, Klisch J, Schmelzeisen R. Brown tumor of the mandible as first manifestation of atypical parathyroid adenoma. J Oral Maxillofac Surg. 2004;62:1024–8.

- Guney E, Yigitbasi OG, Bayram F, Ozer V, Canoz O. Brown tumor of the maxilla associated with primary hyperparathyroidism. Auris Nasus Larynx. 2001;28:369–72.
- Zhao L, Liu JM, He XY, Zhao HY, Sun LH, Tao B, Zhang MJ, Chen X, Wang WQ, Ning G. The changing clinical patterns of primary hyperparathyroidism in Chinese patients: data from 2000 to 2010 in a single clinical center. J Clin Endocrinol Metab. 2013;98(2):721–8.
- Selvi F, Cakarer S, Tanakol R, Guler SD, Keskin C. Brown tumour of the maxilla and mandible: a rare complication of tertiary. Dentomaxillofac Radiol. 2009;38:53–8.
- Kemp AM, Bukvic M, Sturgis CD. Fine needle aspiration diagnosis of osteitis fifibrosa cystica (Brown tumor of bone): a case report. Acta Cytol. 2008;52: 471–4
- Throndson RR, Sexton SB. A mandibular central lesion with unusually rapid growth. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;98:4–9.
- Goshen O, Aviel-Ronen S, Dori S, Talmi YP. Brown tumour of hyperparathyroidism in the mandible associated with atypical parathyroid adenoma. J Jaryngol Otol. 2000:114:302–4.
- Resendiz-Colosia JA, Rodriguez-Cuevas SA, Flores-Diaz R, Juan MH, Gallegos-Hernandez JF, Barroso-Bravo S, Gómez-Acosta F. Evolution of maxillofacial brown tumors after parathyroidectomy in primary hyperparathyroidism. Head Neck. 2008;30:1497–504.
- García-Talavera P, Díaz-Soto G, Montes AA, Villanueva JG, Cobo A, Gamazo C, Ruiz MÁ, González-Selma ML. Contribution of early SPECT/CT to ^{99m}Tc-MIBI double phase scintigraphy in primary hyperparathyroidism: diagnostic value and correlation between uptake and biological parameters. Rev Esp Med Nucl Imagen Mol. 2016;35:351–7.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

